News

Autoantibodies Not Associated With Death in SSc-PAH Patients

A variety of biomarkers are elevated in the serum of patients with systemic sclerosis-pulmonary arterial hypertension (SSc-PAH). Researchers have mostly been studying these markers to determine if they can be used to help diagnose SSc-PAH or if they can serve as targets for new treatments. Alternatively, a study from Northwestern…

Researchers Believe Epigenetics Could Lead to New PAH Therapies

Epigenetics is a fast-growing research field that scientists are applying to many different areas of medicine, such as cancer, peripheral hypertension and asthma. Can the study of epigenetics be useful for understanding and treating pulmonary arterial hypertension as well? A recent article, titled “Epigenetic modulation as a therapeutic…

Balloon Technique Might Help Inoperable Chronic Thromboembolic PAH

A research journal recently reviewed the use of balloon pulmonary angioplasty (BPA), a new option for people with inoperable chronic thromboembolic pulmonary arterial hypertension. The work, titled “Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension“ appeared in the July 7, 2015 issue of…

Pulmonary Hypertension Trailblazer Dr. Stuart Rich is New Program Director at Northwestern Medicine

Northwestern Medicine has appointed Dr. Stuart Rich as director of the newly launched Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, where he will also serve as professor of medicine-cardiology at Northwestern University Feinberg School of Medicine. Dr. Rich, an accomplished innovator in the field of pulmonary hypertension, brings over…